Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Creative Commons License

Marre M. K., SHAW J., BRAENDLE M., Bebakar W. M. W., Kamaruddin N. A., STRAND J., ...More

DIABETIC MEDICINE, vol.26, no.3, pp.268-278, 2009 (SCI-Expanded)

  • Publication Type: Article / Article
  • Volume: 26 Issue: 3
  • Publication Date: 2009
  • Doi Number: 10.1111/j.1464-5491.2009.02666.x
  • Journal Name: DIABETIC MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.268-278
  • Keywords: dipeptidyl peptidase-4, glucagon-like peptide-1 receptor agonist, incretin, insulinotropic, thiazolidinedione, GLUCAGON-LIKE PEPTIDE-1, BETA-CELL FUNCTION, METFORMIN, SAFETY, HYPERGLYCEMIA, GLIMEPIRIDE, REDUCTION, EXENDIN-4, MELLITUS, EFFICACY
  • Open Archive Collection: AVESIS Open Access Collection
  • Akdeniz University Affiliated: Yes

Abstract

To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.